Dr. Eric S. Schaefer, M.D.

Medicare patients and services

Medicare patients, 2024

1,492

Services billed

313,522

Patients’ average age

74

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 36 companies reported 158 payments worth $148,212 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Arkansas →

Industry-funded research

Named as a principal investigator on 21 industry-funded studies in 2025, from 10 companies. The companies reported $1,269,769 in research payments for these studies, mostly to the institutions running them.

• An open label multi center LDK378 roll over protocol for patients who have completed a previous Novartis sponsored LDK378 study and are judged by the investigator to benefit from continued LDK378 treatment
  Novartis Pharmaceuticals Corporation
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
  Eli Lilly and Company · Recruiting · NCT06119581
• A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treat…
  AstraZeneca Pharmaceuticals LP
• A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy f…
  AstraZeneca Pharmaceuticals LP
• A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB N2 NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platin…
  Merck Sharp & Dohme LLC
• A phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with …
  AstraZeneca Pharmaceuticals LP
• HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
  Daiichi Sankyo Inc. · Active, not recruiting · NCT05338970
• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
  Mirati Therapeutics, Inc. · Recruiting · NCT04613596
• Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
  Daiichi Sankyo Inc. · Active, not recruiting · NCT05280470
• A phase III,open label,sponsor blind,randomized study of dato dxd with or without osimertinib versus platinum based doublet chemotherapy for participants with egfr mutated locally advanced or metastatic non small cell…
  AstraZeneca UK Limited

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Rogers

• Daniel S. Bradford, M.D.
• James S. Lopez, M.D.